Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CD274 | Q9NZQ7 | 4/20 | 0.33 |
| ▸ | PDCD1LG2 | Q9BQ51 | 2/20 | 0.33 |
| ▸ | PDCD1 | Q15116 | 2/20 | 0.32 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.32 |
| ▸ | ACACB | O00763 | 1/20 | 0.32 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.31 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.31 |
| ▸ | PDE4A | P27815 | 4/20 | 0.30 |
| ▸ | SYK | P43405 | 3/20 | 0.30 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.30 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.30 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.30 |
| ▸ | TSHR | P16473 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19486191 | 0.76 | SYK (0.34) | PDE4ASYKPDE4BPDE4CPDE4D | |
| SCHEMBL28830304 | 0.74 | FEN1 (0.32) | SYK | |
| SCHEMBL28908986 | 0.74 | FEN1 (0.32) | SYK | |
| SCHEMBL523230 | 0.72 | BRD4 (0.50) | CD274PDCD1LG2PDCD1PDE4ASYK | |
| SCHEMBL1673183 | 0.72 | SYK (0.32) | SYK | |
| SCHEMBL12069210 | 0.70 | IRAK4 (0.34) | CD274PDCD1LG2IRAK4SYK | |
| SCHEMBL3743966 | 0.70 | ACACB (0.41) | ACACBMTNR1AMTNR1B | |
| SCHEMBL18305999 | 0.69 | MTNR1A (0.57) | CD274PDCD1LG2PDCD1MTNR1AMTNR1B | |
| SCHEMBL23557638 | 0.68 | CD274 (0.37) | CD274PDCD1LG2PDCD1MTNR1AMTNR1B | |
| SCHEMBL19045190 | 0.68 | PDE4A (0.33) | PDE4ASYKPDE4BPDE4CPDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8466297-B2 | Manufacturing process for (S)-Pregabalin | SOUKUP MILAN (US) | 2013-06-18 | — | — | US | disclosed |
| US-8466297-B2 | Manufacturing process for (S)-Pregabalin | SOUKUP MILAN (US) | 2013-06-18 | — | — | US | disclosed |
| US-20120123134-A1 | Manufacturing process for (S)-Pregabalin | Drug Process Licensing Associates LLC (US) | 2012-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120123134-A1 | Manufacturing process for (S)-Pregabalin | GABRE, GABRP, GABBR1 | CD274 2671/4885PDCD1LG2 2542/4885PDCD1 2338/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.